							Sheet	1 of 1				
APPLICANT FACSIMILE OF FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE				ATTY DOCKET NO		SERIAL NO.						
REV 7-80 PATENT AND TRADÉMARK OFFICE				MBI-008		09/512,581						
LIST OF PUBLICATIONS CITED BY APPLICANT					APPLICANT							
(Use several sheets if necessary)					Ana M. Soto et al.							
					100 0 9 2001 m				3			
				· · · · · · · · · · · · · · · · · · ·	February 24, 2000	1	1	- 6	}			
U.S. PATENT DOCUMENTS EXAMINER DOCUMENT NUMBER DATE NAME CLASS SUBCLASS FILING									•			
EXAMINER					NAME	CLASS	SUBCLASS		FILING DATE			
INITIAL	 -	200011111110110211	DATE		- Contains	00,00	00000.00	IF APPRO				
	-											
					(
			FORE	IGN PATENT DC	CUMENTS							
				COUNTRY		SUBCLASS TRANSL		LATION				
			DAIL				-Yes NO					
SR	C1	WO 9731531	9/97	PCT								
2.	-											
		OTHERS	(including	Author, Title, Da	te, Pertinent Pages;	Etc.)						
C2 DATABASE EMBLINICI FOTIDE AND PROTEIN SEQUENCES September 11, 1996),						
SR		AC=U50553. Human BRCA2 region;										
	C3 DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES January 30, 1997, AC=Z84572											
SR			juence fro	m PAC 49J10, BF	RCA2 gene region ch	romosom	e 13q12-13	contain	S			
	C4	ESTs;										
DATABASE EMBL MOCLEOTIDE AND PROTEIN SEQUENCES MOVEMBER 1, 1999, AC-Q91							215					
J	The tool of the training train						7201					
5R		DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES January 25, 2000, AC=AL137201 Novel human gene mapping to chromosome 13.					1201					
	C6	DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES March 31, 1999, AC=U95825,										
5R		Human androgen-induced prostate proliferative shutoff associated protein (AS3) mRNA;										
		<u> </u>		·								
							•	-				

Date Considered 14/01

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



APPLICANT FACSIMILE OF FORM PTO-1449 U.S. DEPARTMENT OF ATTY DOCKET NO SERIAL NO.											
REV 7-80			COM	MERCE NT AND TRADEMARK OFFICE	MBI-008		09/512,581				
LIST OF PUBLICATIONS CITED BY APPLICANT APPLICANT APPLICANT											
(Use several sheets if necessary)					Ana M. Soto et al.				٠ ـ ـ		
1/0 m [#]					February 24, 2000	,	GROUP		1		
1 129	* 4	8	-			<u> </u>					
- M	J		U.S	S. PATENT DOCL	JMENTS	_					
EXAMINATION INITIAL	EXAMINE CAT & TO DOCUMENT NUMBER		DATE	NAME		CLASS	SUBCLASS	FILING IF APPRO	DATE OPRIATE		
			FORE	IGN PATENT DO	CUMENTS						
DOCUMENT NUMBER			DATE	COUNTRY			SUBCLASS	TRANS	SLATION		
	-		ļ					YES NO			
<u> </u>								<u> </u>			
_								<u> </u>	<u></u>		
		OTHERS	(including	Author Title Da	te, Pertinent Pages,	Etc.)					
Г	A1				mD gene of Aspers		ulans confe	ers a	/		
SR			=		itivity to DNA damaging agents. Genetics. 1993						
J		Aug;134(4):1085-96;									
	A2		-		nes linked to the ar	_	_				
SR		_	ostate ca	ate cancer cells. J Steroid Biochem Mol Biol. 1997 Nov-Dec;63(4-6)							
	A3	8;	1 Forly o	ana averaggion (during androgen in	duced in	hibition of	prolifor	ection 1		
sn		Geck P, et al. Early gene expression during androgen-induced inhibition of proliferation of prostate cancer cells: a new suppressor candidate on chromosome 13, in the BRCA2-									
		Rb1 locus. J Steroid Biochem Mol Biol. 1999 Jan;68(1-2):41-50;									
CP	Week C at al. A rale for the transcription factors Mbn1 and Swi4 in progression from Gl								om G1		
0,0	to S phase. Science. 1993 Sep 17;261(5128):1551-7;										
sn	Sadar MD, et al. Prostate cancer: molecular biology of early progression to androgen										
J.5.5											
5n	$\lceil \tilde{} \rceil$	Soto AM, et al. Variants of the human prostate LNCaP cell line as tools to study discrete									
		11):545-58;	components of the androgen-mediated proliferative response. <i>Oncol Res.</i> 1995;7(10-11):545-58:								
CP								lls			
SR				Piochem. 1985 Ju							
SR	A8		Thiessen EU. Concerning a familial association between breast cancer and both prostatic								
and uterine malignancies. Cancer. 1974 Oct;34(4):1102-7;											
Examin	er	1 Ranen			Date Considered	101					
EXAMIN	NER:			idered, whether or no			P 609; Draw lir	ne through	citation		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											

	PPLICANT EV 7-80	FACSIMIL	LE OF	FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	E	ATTY DOCKET NO MBI-008	SERIAL NO. 09/512,581			
	LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)					Ana M. Soto et al.				
	PI		,	o deveral endete il liedecca.	Ī	Filing DATE February 24, 2000	GROUP			
Θ-	1	2000	(S)	OTHERS (including Author, Title, D)ate					
L	MA'	B1	S.	Tulinius H, et al. Risk of prostate, ov		ancer among relatives of				
Ž	women with breast cancer. BMJ. 1992 Oct 10;305(6858):855-7;									
	Waddick KG, et al. Innovative treatment programs against cancer: II. Nuclear factor-kappaB (NF-kappaB) as a molecular target. <i>Biochem Pharmacol</i> . 1999 Jan 1;57(1):9-17;									
	sr	В3		Zhang Y, et al. Molecular characterist promoter. <i>Biochim Biophys Acta</i> . 19		· · · · · · · · · · · · · · · · · · ·	-			
			П							
			П							
			П							
			П							
r			П							
十			П			. <u> </u>				
			П							
		\top	П							
			П							
			П							
E	xamine	er er	_/	Randon	D	Pate Considered	/			
E	EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									